- Aterian Investment Partners has completed the acquisition of Contract Pharmaceuticals Ltd. Canada (CPL), a North American contract development and manufacturing organization (CDMO) specializing in non-sterile liquid and semi-solid dosage forms.
- CPL, based in Mississauga, ON, has strong ties with 15 of the top 20 global pharmaceutical companies and operates FDA and Health Canada-registered facilities.
Aterian Investment Partners, a private investment firm, has announced the acquisition of Contract Pharmaceuticals Ltd. Canada (CPL). CPL is a North American contract development and manufacturing organization (CDMO) that specializes in non-sterile liquid and semi-solid dosage forms.
CPL is based in Mississauga, ON, and has established relationships with 15 of the top 20 global pharmaceutical companies. The company supports its customers through FDA and Health Canada-registered facilities and sells into North America, the EU, Japan, Australia, Mexico, Brazil, and the Middle East.
The Aterian team expressed their excitement about the successful closure of this transaction. They believe that with Aterian’s investment in people, technology, and processes, CPL is well-equipped to enter its next phase of growth and to drive industry transformation by providing further value to customers.
Jan Sahai, CEO of CPL, stated, “With Aterian’s backing, we are laser-focused on innovation, growth, and delighting our customers to further expand our unmatched position in the non-sterile liquid and topical drug products space. This collaboration undoubtedly strengthens our positioning in serving our customers and being the trusted partner to pharmaceutical companies around the world.”
Jay Taunk, Principal at Aterian, added, “CPL represents Aterian’s thirteenth investment in the life sciences, personal care, and nutrition segments. We are thrilled to support CPL and look forward to working with the management team to continue the Company’s growth trajectory.”
Overview of outsourcing trends 
